Full Press Release Details
SAN DIEGO , Dec. 11, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) has confidentially submitted a draft registration statement on Form 10 related to its potential divestiture of GRAIL to the U.S. Securities and Exchange Commission, pursuant to an order Illumina received from the European Commission (EC) directing the company to divest GRAIL.
Submission of this registration statement is an important next step in evaluating divestiture options for GRAIL. Illumina is committed to resolving all issues regarding GRAIL in a timely manner, with the objective of achieving the maximum value for shareholders and the best outcome for GRAIL.
Under the terms of the EC's order, Illumina is permitted to explore a range of structures including, but not limited to, a third-party sale or a capital markets transaction. Illumina is leading the divestiture process with the assistance of financial and legal advisors.
This release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which any such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Cautionary Note on Statements of Opinion In addition to forward-looking statements, this release contains statements of opinion with which all may not agree.
Illumina is improving human health by unlocking the power of the genome. In 2023 we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X (Twitter) , Facebook , LinkedIn , Instagram , TikTok , and YouTube .
Investors: Salli Schwartz 858-291-6421 [email protected]
Media: David McAlpine 347-327-1336 [email protected]
SOURCE Illumina, Inc.